Navigation Links
New treatment regimen shown effective against advanced ovarian cancer
Date:6/6/2010

CHICAGO (June 6, 2010) Newly reported results from a major clinical trial show that adding bevacizumab (Avastin) to standard frontline chemotherapy for women with advanced ovarian cancer and then continuing a maintenance dose of the drug afterwards significantly extends progression-free survival. Women receiving the new treatment regimen saw no worsening of their disease for 14.1 months, compared to 10.3 months for women receiving standard therapy.

The international, multi-center, randomized, double-blind, placebo-controlled Phase III clinical trial was conducted by a network of researchers known as the Gynecologic Oncology Group (GOG) and sponsored by the U.S. National Cancer Institute. The trial results were presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO).

The trial marked the first time a molecularly targeted agent has been part of a validated strategy for treating advanced ovarian cancer. It was also the first time a maintenance dosing approach involving any therapy has been outlined for the disease. Additionally, ongoing analysis of the trial data may offer insights into genetically defined subgroups of patients who benefited more than others, pointing to the possibility of more personalized, even more effective treatment for ovarian cancer in the future.

"Ovarian cancer remains one of the most deadly cancers in women, so this clinical advance is particularly welcome," says Robert A. Burger, M.D., lead investigator on the GOG trial and director of the Women's Cancer Center at Fox Chase Cancer Center. "Before this, we could treat ovarian cancer patients only with surgery and chemotherapy involving relatively toxic agents. Now, we have a third type of more targeted therapy to offer these patients, potentially opening the way to even greater progress in years to come."

According to the American Cancer Society, approximately 22,000 new cases of ovarian cancer will be diagnosed this year, and about 15,000 women will die from their disease. Ovarian cancer is the eighth most common cancer among women, excluding non-melanoma skin cancers. It ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system.

The trial, dubbed GOG-0218, enrolled 1,873 previously untreated women with advanced disease from 336 sites in four countries (U.S., Canada, South Korea, and Japan). The women were randomly assigned to one of three treatment protocols: standard chemotherapy (carboplatin and paclitaxel) plus placebo, followed by placebo maintenance for an up to 10 additional months; standard chemotherapy plus bevacizumab followed by placebo maintenance; and standard chemotherapy plus bevacizumab followed by bevacizumab maintenance. The type and frequency of bevacizumab-associated side effects were similar to those seen in previous cancer studies involving the drug.

Bevacizumab, a humanized monoclonal antibody, is an angiogenesis inhibitor, meaning that the drug limits tumor growth by interfering with the formation of new blood vessels to supply the tumor with needed nutrients. It acts by inhibiting the function of a naturally occurring protein called vascular endothelial growth factor, or VEGF, which is overproduced in many cancers and stimulates new blood vessel formation.


'/>"/>

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-815-7828
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. New treatment method safe, effective for advanced melanoma patients
2. Combination treatment regimen not effective against advanced melanoma
3. Researchers Report Treatment Headway Against Lung Cancer
4. Nasendoscopy proves useful in predicting treatment success in sleep apnea patients
5. Mount Sinai researchers approaching universal treatment for all strains of influenza
6. New Website Created Just For Car Accident Victims… Reveals Chiropractic Treatment Is Extremely Effective For Whiplash, Neck and Back Pain
7. The Harley Medical group launches exclusive treatment for stretch marks and scars
8. Local Walgreen's Drug Stores Now Stock ZymaDerm™ The Painless Treatment for Molluscum Contagiosum
9. UT Southwestern investigators perform head-to-head comparison of incontinence treatments
10. New cancer guidelines: Exercise during and after treatment is now encouraged
11. Acne Treatment Reviewed by Leading Dermatologists in Honor of Acne Awareness Month
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... , ... May 24, 2016 , ... ... physical disease or injury that focuses on repairing the musculoskeletal and neuromuscular systems ... an emphasis on functional restoration, NYDNRehab began providing treatments for physical therapy in ...
(Date:5/24/2016)... ... May 24, 2016 , ... Growing in popularity, more and more ... products are available and easily accessible. Whether someone chooses to cut gluten out of ... certain diet, King Kullen Grocery stocks their shelves with many different gluten-free products all ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... ... Peggy Kinst, a wellness specialist for forty years and a trainer for Ageless ... Sharon Kleyne Hour Radio Talk Show on May 16, 2016. , Formerly a ...
(Date:5/24/2016)... Forest Lake, Minnesota (PRWEB) , ... May 24, ... ... his 13th mission trip to the Dominican Republic on September 21, 2016. Dr. ... Biology from Northwestern, serves with ChiroMission, a not-for-profit organization promoting health and wellness ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... safety signs and safety labels , has been featured in the ... Labels.” , The eiXtra e-newsletter provides electroindustry professionals with manufacturer, regulatory, and standardization ...
Breaking Medicine News(10 mins):
(Date:5/20/2016)... 20, 2016 ReportsnReports.com adds ... Medical Devices of its online business intelligence library. ... the current state of the Titrator industry. The ... like definitions, classifications, Specifications, applications and industry chain ... like Raw Material Suppliers, Equipment Suppliers, Manufacturing Cost ...
(Date:5/20/2016)... , May 20, 2016 ... Pipeline Review, H1 2016" market research report with ... Psoriasis (Psoriasis Vulgaris), complete with comparative analysis at ... of action (MoA), route of administration (RoA) and ... news and press releases. It also reviews key ...
(Date:5/19/2016)... 2016 According to a new market research ... (U.S., Germany , France , ... and Japan )", published by MarketsandMarkets, The market ... CAGR of 13.9% from 2016 to 2021.      (Logo: ... data Tables spread through 26 Pages and in-depth TOC on ...
Breaking Medicine Technology: